Lanzhou Foci Pharmaceutical Co Ltd (002644) — Working Capital to Net Assets Ratio
Lanzhou Foci Pharmaceutical Co Ltd (002644) has a Working Capital to Net Assets ratio of 48.6% as of September 2025. Working capital of CN¥896.65 Million (current assets of CN¥1.32 Billion minus current liabilities of CN¥426.17 Million) is measured against net assets of CN¥1.85 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See 002644 equity to assets ratio to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Lanzhou Foci Pharmaceutical Co Ltd Working Capital to Net Assets (2007–2024)
This chart shows how Lanzhou Foci Pharmaceutical Co Ltd's Working Capital to Net Assets ratio has evolved across 18 annual periods from 2007 to 2024. As of September 2025, the ratio stands at 48.6%, reflecting working capital of CN¥896.65 Million against net assets of CN¥1.85 Billion CNY. Check tangible net worth ratio of Lanzhou Foci Pharmaceutical Co Ltd to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Lanzhou Foci Pharmaceutical Co Ltd (2007–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Lanzhou Foci Pharmaceutical Co Ltd from 2007 to 2024, covering 18 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see 002644 stock market capitalisation.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 46.4% | CN¥842.16 Million | CN¥1.81 Billion | CN¥1.22 Billion | CN¥379.73 Million | ▲ +2.8 pp |
| 2023 | 43.6% | CN¥771.18 Million | CN¥1.77 Billion | CN¥1.24 Billion | CN¥467.69 Million | ▼ -0.3 pp |
| 2022 | 43.9% | CN¥760.58 Million | CN¥1.73 Billion | CN¥1.29 Billion | CN¥530.49 Million | ▲ +3.3 pp |
| 2021 | 40.5% | CN¥659.79 Million | CN¥1.63 Billion | CN¥1.03 Billion | CN¥374.84 Million | ▲ +0.7 pp |
| 2020 | 39.8% | CN¥631.71 Million | CN¥1.59 Billion | CN¥1.05 Billion | CN¥422.44 Million | ▲ +3.2 pp |
| 2019 | 36.6% | CN¥551.86 Million | CN¥1.51 Billion | CN¥1.04 Billion | CN¥484.48 Million | ▲ +7.5 pp |
| 2018 | 29.1% | CN¥419.34 Million | CN¥1.44 Billion | CN¥926.53 Million | CN¥507.19 Million | ▼ -24.4 pp |
| 2017 | 53.5% | CN¥726.75 Million | CN¥1.36 Billion | CN¥1.10 Billion | CN¥370.92 Million | ▼ -46.0 pp |
| 2016 | 99.5% | CN¥1.28 Billion | CN¥1.29 Billion | CN¥1.42 Billion | CN¥136.16 Million | ▲ +24.6 pp |
| 2015 | 74.9% | CN¥923.49 Million | CN¥1.23 Billion | CN¥1.01 Billion | CN¥87.56 Million | ▲ +13.0 pp |
| 2014 | 61.9% | CN¥455.05 Million | CN¥735.22 Million | CN¥569.09 Million | CN¥114.04 Million | ▲ +10.7 pp |
| 2013 | 51.2% | CN¥359.96 Million | CN¥703.37 Million | CN¥520.76 Million | CN¥160.80 Million | ▲ +1.6 pp |
| 2012 | 49.6% | CN¥335.00 Million | CN¥675.53 Million | CN¥467.71 Million | CN¥132.71 Million | ▼ -10.9 pp |
| 2011 | 60.5% | CN¥392.19 Million | CN¥648.08 Million | CN¥559.73 Million | CN¥167.55 Million | ▲ +26.7 pp |
| 2010 | 33.8% | CN¥110.50 Million | CN¥326.46 Million | CN¥226.80 Million | CN¥116.30 Million | ▲ +14.5 pp |
| 2009 | 19.4% | CN¥49.06 Million | CN¥252.96 Million | CN¥207.13 Million | CN¥158.06 Million | ▲ +24.8 pp |
| 2008 | -5.4% | CN¥-11.68 Million | CN¥216.81 Million | CN¥161.45 Million | CN¥173.13 Million | ▲ +7.4 pp |
| 2007 | -12.8% | CN¥-25.00 Million | CN¥195.20 Million | CN¥114.56 Million | CN¥139.56 Million | — |